Additionally, several reports indicated that the activation of Erk1/2 by ROS leads to induction of the cell survival and proliferation in different tumor types such as melanoma, breast cancer, ovarian cancer and leukemia [27]. Here, MAPK3 is linked to breast carcinoma.